Kellerhals Carrard has acted as legal counsel to Stille, a medical device company, in acquiring all shares in Switzerland-based S&T, a manufacturer of microsurgical instruments, in exchange for CHF 6 million paid in cash upon completion of the transaction and financed through Stille’s existing cash liquidity and bank loans. In addition to, CHF 2.5 million […]
Advestra acted as legal counsel to One Equity Partners, a middle market private equity firm, in completing the acquisition of a 29 percent stake in Cicor Technologies (SIX Swiss Exchange: CICN), a Swiss provider of electronic
Givaudan, a Swiss manufacturer of flavours, fragrances and active cosmetic ingredients, has acquired a 25% stake in B. Kolormakeup & Skincare, an Italy-based company specialized in developing and producing end to end products in make-up and
Heuking Kühn Lüer Wojtek acted as legal counsel to Prose Group on the sale of its testing division, based in Germany and Switzerland, to Germany-based Tüv Süd, for an undisclosed consideration. &
Kuehne & Nagel International, a Switzerland-based provider of transport, logistics and supply chain management solutions, enters into a binding agreement to acquire 100% of the shares in Salmosped. The Oslo-based company is a Norwegian perishables freight
Switzerland based Dietrich Engineering Consultants has announced the acquisition of UK based Biotech and pharmaceutical system provider, Extract Technology, from Wabash National Corp, a U.S. listed trailer manufacturing company. The acquisition included Extract Technology
Switzerland-based global private markets firm, Partners Group, has, on behalf of its clients, agreed to acquire Pharmathen, a Greece-based pharmaceutical company, from international U.S. based investment firm BC Partners. The transaction values Pharmathen at
Ermenegildo Zegna Group, the privately-held Italian fashion company, will go public on the New York Stock Exchange later this year by way of a merger with Investindustrial Acquisition Corp., a special purpose acquisition corporation – or
Kuros Biosciences, a bone graft technologies company, has entered into a royalty purchase agreement with Xoma Corporation, under which Xoma has purchased a proportion of the potential future pre-commercial milestone payments and all the potential
HEB Swiss Investment, a Zurich-based holding company owned by a German private investor, has entered into an agreement to sell its major stake (29.3 %) in listed Cicor Technologies (SIX Swiss Exchange: CICN) to One Equity Partners.
